The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Chemotherapy-Associated Thrombotic Microangiopathy (TMA)

Recognition and management of TMA syndromes triggered by chemotherapeutic agents

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is Chemotherapy-Associated Thrombotic Microangiopathy (TMA)?

Chemotherapy-associated TMA characterized by microangiopathic hemolytic anemia with schistocytes, thrombocytopenia and organ damage.

Pathophysiology involves endothelial injury, complement activation, von Willebrand factor abnormalities and microvascular thrombosis.

Common implicated agents include mitomycin C, gemcitabine, calcineurin inhibitors (cyclosporine, tacrolimus), VEGF inhibitors (bevacizumab).

Proteasome inhibitors (bortezomib, carfilzomib) and immune checkpoint inhibitors recently identified as triggers.

Distinct from thrombotic thrombocytopenic purpura (TTP) which is ADAMTS13-mediated and atypical HUS which is complement-mediated.

Symptoms

Microangiopathic hemolytic anemia with elevated LDH, decreased haptoglobin and schistocytes on peripheral smear.
Thrombocytopenia of variable severity from mild to severe.
Acute kidney injury frequently present and may be predominant manifestation.
Neurological involvement including headache, confusion, seizures in severe cases.
Hypertension, particularly with VEGF inhibitor-associated TMA, requiring management.

Risk Factors

Specific chemotherapy agents with established TMA association including mitomycin C, gemcitabine.
Cumulative drug exposure increases risk for many agents.
Hematopoietic stem cell transplantation creates additive risk through conditioning, calcineurin inhibitors.
Underlying complement dysregulation may predispose to TMA in setting of triggering exposures.
Pre-existing renal dysfunction or hypertension increases vulnerability.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • New onset hemolytic anemia, thrombocytopenia or kidney injury during cancer treatment warrants TMA evaluation.
  • Severe TMA with major organ dysfunction requires urgent intensive care and specialty consultation.
  • Differential diagnosis from TTP requires ADAMTS13 testing if uncertain to guide treatment urgency.
  • Refractory TMA despite offending agent withdrawal may warrant complement testing and eculizumab consideration.
  • Long-term follow-up monitors renal function recovery and risk of recurrence with future treatments.

Treatment Methods

01
Immediate discontinuation of suspected offending agent represents primary intervention.
02
Supportive care with red cell and platelet transfusions for severe cytopenias though platelet transfusion may worsen TMA.
03
Renal replacement therapy for severe acute kidney injury.
04
Eculizumab complement inhibitor for refractory cases or those with documented complement dysregulation.
05
Comprehensive management including blood pressure control particularly in VEGF-inhibitor TMA, ADAMTS13 testing to exclude TTP, complement function testing, monitoring for organ recovery, careful selection of subsequent cancer treatments avoiding implicated agents when possible, alternative chemotherapy regimen selection and ongoing monitoring for late complications and TMA recurrence with subsequent treatments optimizes outcomes from this serious treatment-related complication.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.